Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results

–NUZYRA™ (omadacycline) approved by FDA for the treatment of CABP and ABSSSI —
— SEYSARA™ (sarecycline) approved by FDA for the treatment of moderate to severe acne vulgaris —
— Company planning for a February 2019 NUZYRA U.S. launch –
BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today reported financial results and provided an update on financial, clinical, commercial and regulatory filing activities for the quarter ended September 30, 2018.
“It has been an exciting and productive period for Paratek during which we ac…

READ FULL TEXT